Investigational Medicinal Product (IMP) Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which is responsible for inserting the virus’s genetic material into the DNA of the infected cell. Gammora stimulates the integration of multiple HIV DNA fragments into the host cell’s genomic DNA, to an extent that triggers the self-destruction of the infected cell, called apoptosis. The peptide, produced by San Diego, California -based PolyPeptide Labs, has the potential to cure HIV infected patients, by destroying all cells carrying the HIV virus-genome. As opposed to the commercially available retroviral treatments, the so-called “cocktail,” which merely suppress the spreading of the virus, but do not cure the infection.
Views: 16386 Zion Medical
As a full-service contract development and manufacturing organisation (CDMO) for investigational medicinal products (IMP), Custom Pharma Services covers the full spectrum of activities from process development through commercial manufacturing. Custom’s advanced facilities can produce tablets, caplets, capsules (immediate and modified release) and powders, with an annual capacity of more than 1.5 billion tablets and 250 million capsules for both clinical and commercial use. Custom Pharma offer solid dose forms including controlled drugs, certain hormonal products, specials, veterinary medicinal products. Fully certified in the UK and Europe, Custom Pharma Services is your one-stop resource for contract development, remedial, analytical services and pharmaceutical manufacturing. http://www.custompharma.co.uk ------------------------------------------------------- Soundtrack Music: In The Field by Audionautix is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) Artist: http://audionautix.com/
Views: 422 Custom Pharma
Rango Dietrich's new single Shipping - 47. Transfers of Investigational Medicinal Products from One Trial Site to Another with a promo sample. Buy this Hörbücher record at: Amazon: http://www.amazon.de/s/field-keywords=Rango+Dietrich%20Shipping+-+47.+Transfers+of+Investigational+Medicinal+Products+from+One+Trial+Site+to+Another Spotify: http://open.spotify.com/track/4GaxG3t2CsHhyJ7B8vJNve Djshop.de: http://www.djshop.de/Download-Rango+Dietrich-Shipping+-+47.+Transfers+of+Investigational+Medicinal+Products+from+One+Trial+Site+to+Another/ex/s~details,u~10069920,p1~mp3/xe/details.html Djtunes.com: http://www.djtunes.com/music?view=tracks&sorf=relevance&searchq=Rango+Dietrich+Shipping+-+47.+Transfers+of+Investigational+Medicinal+Products+from+One+Trial+Site+to+Another Start your own monetized channel now and earn money with YouTube: http://goo.gl/bJs4Rb Feiyr.com - Sell your Music and eBooks online! Register online for free, upload your songs and start selling them on 300 online stores worldwide. A team of professional label managers will support you during the release process as well as when it comes to setting up promo campaigns. This is how digital music distribution works. Start now! Feiyr: http://www.feiyr.com Feiyr @ Twitter: https://twitter.com/feiyr Feiyr @ Instagram: https://instagram.com/feiyr/ Artist: Rango Dietrich Title: Shipping - 47. Transfers of Investigational Medicinal Products from One Trial Site to Another Date: 2014-03-07 Style: Hörbücher ID: 10243665 ISRC: DEAR41413993 Distributed by: https://www.feiyr.com/digital_music_distribution This video was published on YouTube with the authorization of Pharmaudio Guidelines. If you want to request a delete of this video, please contact https://www.feiyr.com/en/contact.html
Views: 9 Hörbücher TV
உயிர்க்கொல்லியான எய்ட்ஸ் நோய்க்கு இஸ்ரேலைச் சேர்ந்த ஜியோன் நிறுவனம் மருந்து கண்டுபிடித்துள்ளதாக அறிவித்திருக்கிறது. எச்.ஐ.வி. வைரஸ் எய்ட்ஸ் பாதிப்புக்கு காரணமாக உள்ளது. Health new on HIV Drug Gammora Offers Potential Cure. Investigational Medicinal Product (IMP) Gammora is a synthetic peptide compound derived from the HIV enzyme integrase, which is responsible for inserting the virus’s genetic material into the DNA of the infected cell. Gammora stimulates the integration of multiple HIV DNA fragments into the host cell’s genomic DNA, to an extent that triggers the self-destruction of the infected cell, called apoptosis. The peptide, produced by San Diego, California -based PolyPeptide Labs, has the potential to cure HIV infected patients, by destroying all cells carrying the HIV virus-genome.
Views: 4315 Smart Tips Tamil
Somerset House Consultants has long experience of design and management of pharmaceutical development, manufacturing, and quality assurance programmes. Founded in the UK in 2001, we have an international client base covering Europe, US, Japan, Australia and India. Our expertise covers Active Pharmaceutical Ingredients, Investigational Medicinal Products, sterile and non-sterile dosage forms and biotechnology products. Our services include: •Setting up GMP-compliant Quality Assurance systems •Responding to FDA and EMEA deficiency letters •Supplier audits •Qualified Person Release of Active Pharmaceutical Ingredients (API), Investigational Medicinal Products (IMP) and commercial products •Manufacture and Release of Clinical Trial Supplies •Contractor selection and management •Drafting GMP-compliant Quality Agreements with suppliers and contractors •GMP compliance •Interim management •Staff training
Views: 1076 SomersetHouseGMP
Mastering Immunity Europe 2017 Prof. Farzin Farzeneh, Professor of Molecular Medicine, King’s College London, UK A large number of different classes of tumour-associated antigens provide specific targets for immune therapy of cancer. These include antigens expressed by oncogenic viral vectors such as Human Papilloma Virus (HPV), as well as a whole array of mutated oncogenes, abnormally glycosylated proteins and carcino-embryonic gene products that are expressed at elevated levels in different malignancies. In addition to these common antigenic targets, recent data has demonstrated the presence of other, entirely patient and tumour specific mutations. Both the common and the private tumour-associated antigens provide potential targets for the immune mediated eradication of cancer. Such immune therapy strategies are of particular relevance to the eradication of the residual cancer cells, which can contribute to possible relapse and recurrence, despite a successful initial response to therapy. The most promising of the new immune therapy based approaches include the use of antibody based blockade of immune inhibitory check points (e.g. anti-CTLA4, anti-PD1/PDL1, etc.). The inhibition of these feedback loops allows the stimulation and expansion of specific populations of tumour specific T cells. An alternative and highly promising new form of immune therapy is the generation of autologous and allogeneic T cells expressing antigen specific T cell receptors, including chimeric antigen receptors (CAR T-cells), that are able to recognise and lyse tumour cells. Other strategies showing moderate clinical efficacy include the use of autologous dendritic cells that are pulsed with tumour-associated RNA, proteins and peptides, or with whole tumour lysate. Alternatively, autologous cancer cells can themselves be genetically modified to serve as whole cell vaccines. Yet other exciting new developments include the identification of new adjuvants and vaccination strategies for cancer specific induction of protective and therapeutic cellular immunity. The combination of such new vaccination strategies, combined with identification of individualised cancer specific mutations (e.g. by exome sequencing, RNAseq, whole genome sequencing, etc.) is holding out the promise of substantially more effective vaccination strategies. Given the rapid pace of these developments, the treatment of many cancers is now poised for dramatic improvements. Farzin Farzaneh received his MSc in 1977 (University of Aberdeen) and his PhD in 1979 (University of Sussex). Following a number of Postdoctoral Fellowships awarded by Beit Memorial Foundation, EMBO and the MRC at the Universities of Amsterdam and Sussex, he joined the Faculty at King’s College London in 1985. He was awarded the Chair in Molecular Medicine (1996), elected to the Fellowship of the Royal College of Pathologists (1996), and to the Royal Society for the Encouragement of Arts, Manufacture & Commerce in 1997. He is a co-founder of the International Society for Cell and Gene Therapy of Cancer (ISCGT), and served as its president in 2007/2008. Having studied the functional analysis of the genome and interactions between cancer and the immune system, he established a GMP facility for the production of Cell and Gene Therapy based Investigational Medicinal Products (IMPs), at King’s College London in 2001. This laboratory has produced the largest number of viral vectors for cell and gene therapy clinical trials in Europe. Farzin has been the European Editor for Experimental Biology and Medicine since 2006, has published two edited books (the Functional Analysis of the Genome and Cancer Gene Therapy), plus over two hundred papers with an average of more than29 citations each. He was awarded the Distinguished Scientist Award by the US Society for Experimental Biology and Medicine in 2016. He has recently been appointed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to Commission on Human Medicines: Clinical Trials, Biologicals & Vaccines (CTBV) Expert Advisory Group. He has a very active programme of research supported by research councils, government and charitable organisations as well as the biotech and pharmaceutical industry.
Views: 622 ProImmune thinkpeptides